Treatment Approaches in Non-Driver Lung Adenocarcinoma

Treatment Approaches in Non-Driver Lung Adenocarcinoma

Episodes

Specialty:

All

Year:

All

EP. 1: First-Line Chemotherapy Options in Lung Adenocarcinoma

October 31st 2016

EP. 2: Non-Driver Mutation Non-Squamous NSCLC

October 31st 2016

EP. 3: Potential Upfront and Maintenance Strategies in NSCLC

October 31st 2016

EP. 4: Options in Second-Line Non-Squamous NSCLC

October 31st 2016

EP. 5: PD-L1 Status in Second-Line Lung Adenocarcinoma

October 31st 2016

EP. 6: Non-Driver NSCLC: Clinical Decisions in Rapidly Progressing Disease

October 31st 2016

EP. 7: Differentiating Among Anti-VEGF Therapies in Lung Adenocarcinoma

October 31st 2016

EP. 8: Lung Adenocarcinoma: Patient Selection With Ramucirumab vs Nintedanib

October 31st 2016

EP. 9: Practical Implications of the LUME-Lung 1 Findings

October 31st 2016

EP. 10: Practical Considerations With Nintedanib in Lung Adenocarcinoma

October 31st 2016

EP. 11: Nintedanib in Lung Adenocarcinoma: Managing Toxicities

October 31st 2016

EP. 12: Cost Considerations in Non-Driver NSCLC Management

October 31st 2016

EP. 13: The Future of Non-Driver Lung Adenocarcinoma

October 31st 2016

Trending on OncLive

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer

European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma

ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer

FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma